Blog

The pCODR does not recommend the funding of aflibercept when used in combinaiton with an irinotecan and a fluoropyrimidine (FOLFIRI) ...

[:content [\T \h \e \space \p \a \n \- \C \a \n \a \d \i \a \n \space \O \n \c \o \l \o \g \y \space \D \r \u \g \space \R \e \v \i \e \w \space \( \p \C \O \D \R \) \space \t \r \a \n \s \f \e \r \r \e \d \space \t \o \space \C \A \D \T \H \space \o \n \space \A \p \r \i \l \space \1 \, \space \2 \0 \1 \4 \. \space \T \h \e \space \k \e \y \space \r \e \a \s \o \n \space \f \o \r \space \t \h \e \space \t \r \a \n \s \f \e \r \space \w \a \s " ..."]]

[:content [\N \I \C \E \space \h \a \s \  \r \e \c \o \m \m \e \n \d \e \d \  \e \l \t \r \o \m \b \o \p \a \g \space \o \l \a \m \i \n \e \  \( \R \e \v \o \l \a \d \e \, \space \G \S \K \) \space \a \s \space \a \n \space \o \p \t \i \o \n \space \f \o \r \space \t \r \e \a \t \i \n \g \space \s \o \m \e \space \a \d \u \l \t \s \space \w \i \t \h \space \t \h \e \space \b \l \e \e \d \i \n \g \space \d \i \s \o \r \d \e \r \space \c \h \r \o \n \i \c \space \i \m \m \u \n \e \space \( \i \d \i \o \p \a \t \h \i \c \) \space \t \h \r \o \m \b \o \c \y \t \o \p \e \n \i \c \space \p \u \r \p \u \r \a \  \i \n " ..."]]

[:content [\1 \1 \space \F \e \b \r \u \a \r \y \space \2 \0 \1 \4 \space \- \  \D \r \u \g \space \m \a \k \e \r \space \C \e \l \g \e \n \e \space \C \o \r \p \o \r \a \t \i \o \n \  \s \a \i \d \space \T \u \e \s \d \a \y \space \t \h \a \t \space \H \e \a \l \t \h \space \C \a \n \a \d \a \space \h \a \s \space \a \p \p \r \o \v \e \d \space \P \o \m \a \l \y \s \t \space \o \r \a \l \space \t \h \e \r \a \p \y \space \( \p \o \m \a \l \i \d \o \m \i \d \e \space \c \a \p \s \u \l \e \s \) \space \i \n \space \c \o \m \b \i \n \a \t \i \o \n " ..."]]

The pCODR Expert Review Committee (pERC) has not recommended the funding of Zaltrap (aflibercept) when used in combination with an ...

Janssen Inc. announced today Health Canada has approved Imbruvica (ibrutinib) for the treatment of the blood cancer chronic lymphocytic leukemia (CLL). ...

The complete Guidelines for Manufacturers on Application Fees for the CADTH pan-Canadian Oncology Drug Review are now posted on the CADTH website, along with ...

[:content [\N \I \C \E \space \h \a \s \space \i \s \s \u \e \d \  \n \e \w \space \d \r \a \f \t \space \g \u \i \d \a \n \c \e \  \t \h \a \t \space \d \o \e \s \space \n \o \t \space \r \e \c \o \m \m \e \n \d \space \C \e \l \g \e \n \e \' \s \space \l \e \n \a \l \i \d \o \m \i \d \e \space \( \R \e \v \l \i \m \i \d \) \space \f \o \r \space \t \r \e \a \t \i \n \g \space \p \a \t \i \e \n \t \s \space \w \i \t \h \  \m \y \e \l \o \d \y \s \p \l \a \s \t \i \c \space \s \y \n \d \r \o \m \e \s \space \( \M \D \S \) \. \  \  \T \h \i \s \space \a \p \p \r \a \i \s \a \l \space \f \o \c \u \s \e \s \space \o \n " ..."]]

Bayer has announced Health Canada’s expanded approval of Stivarga (regorafenib) to include its use for the treatment of adult patients with metastatic ...

[:content [\1 \0 \space \M \a \r \c \h \space \2 \0 \1 \4 \space \- \  \P \e \o \p \l \e \space \i \n \space \O \n \t \a \r \i \o \space \a \n \d \space \A \t \l \a \n \t \i \c \space \C \a \n \a \d \a \space \f \a \c \e \space \f \i \n \a \n \c \i \a \l \space \h \a \r \d \s \h \i \p \space \t \h \a \t \space \o \t \h \e \r \space \C \a \n \a \d \i \a \n \s \space \d \o \n \' \t \space \w \h \e \n \space \i \t \space \c \o \m \e \s \space \t \o " ..."]]

[:content [\A \f \i \n \i \t \o \r \space \( \e \v \e \r \o \l \i \m \u \s \) \space \i \s \space \n \o \t \space \r \e \c \o \m \m \e \n \d \e \d \space \a \s \space \a \n \space \N \H \S \- \f \u \n \d \e \d \space \t \r \e \a \t \m \e \n \t \space \f \o \r \space \a \space \t \y \p \e \space \o \f \space \a \d \v \a \n \c \e \d \space \b \r \e \a \s \t \space \c \a \n \c \e \r \space \b \e \c \a \u \s \e \space \i \t \space \i \s \space \n \o \t " ..."]]

[:content [\T \h \e \space \C \a \n \a \d \i \a \n \space \p \E \R \C \space \h \a \s \space \r \e \c \o \m \m \e \n \d \e \d \space \t \h \e \space \f \u \n \d \i \n \g \space \o \f \space \b \r \e \n \t \u \x \i \m \a \b \space \v \e \d \o \t \i \n \space \( \A \d \c \e \t \r \i \s \) \space \f \o \r \space \u \s \e \space \b \y \  \p \a \t \i \e \n \t \s \space \w \i \t \h \space \H \o \d \g \k \i \n \' \s \space \l \y \m \p \h \o \m \a \space \c \o \n \d \i \t \i \o \n \a \l \space \o \n \space \i \t \s " ..."]]

The CADTH pCODR program is currently seeking nominations for a Health Economist to sit as a member of the pCODR Expert Review ...

Ariad Pharmaceuticals, Inc., today announced that Health Canada has approved the use of Iclusig (as ponatinib hydrochloride) in Canada for the treatment of adult patients with ...